Retrospective Chart Analysis in the Effective Use of FloSeal in Post-Operative Joint Replacements

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Desert Orthopedic Center Medical Research Foundation.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by:
Desert Orthopedic Center Medical Research Foundation
ClinicalTrials.gov Identifier:
NCT00958945
First received: August 12, 2009
Last updated: August 13, 2009
Last verified: August 2009
  Purpose

The purpose of this analysis is to compare Hemoglobin and Hematocrit levels following total hip or knee arthroplasty. The utilization of FloSeal intraoperatively will improve hemostasis postoperatively. Decreasing bleeding time will decrease the drop in level of Hemoglobin and Hematocrit which usually occurs postoperatively.


Condition
Total Knee Arthroplasty
Arthroplasty, Replacement, Hip

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Retrospective & Prospective Evaluation/Analysis of Hb/Hct in Patients Having Received FloSeal (5ml &10ml) When Undergoing Total Knee or Total Hip Arthroplasty

Resource links provided by NLM:


Further study details as provided by Desert Orthopedic Center Medical Research Foundation:

Estimated Enrollment: 500
Study Start Date: September 2009
Groups/Cohorts
FloSeal - Knee - control
100 Historical Control Patients, knees - no FloSeal (retrospective)
FloSeal - Knee - 5ml
100 Patients, knees - 5mL FloSeal (retrospective)
FloSeal - Knee - 10ml
100 Patients, knees- 10mL FloSeal (prospective)
FloSeal - Hip - Control
100 Historical Control patients, hips—no FloSeal (retrospective)
FloSeal - Hip - 5ml
100 retrospective patients, hips—5mL of FloSeal (retrospective)

Detailed Description:

Retrospective Analysis of charts on patients having undergone Total Hip or Total Knee Arthroplasty. During the patient's hospitalization, lab values of Hg and Hct will be recorded for further analysis. Preoperative levels will be also noted to establish baselines.

Primary Data interest will be Hemoglobin (Hgb) level documented during hospitalization along with Hematocrit (HCT) and Red Blood Cell (RBC) data also collected.

Secondary Data gathered will consist of the following:

  • patient Demographics
  • Component Profile
  • Length of Stay
  • Anesthesia used
  • Anesthesiologist
  • EBL
  • drain type
  • Amount of drainage fluid recorded at 12 hour increments until discharge
  • Amount of FloSeal used
  • Type of Arthroplasty

    500 patients in Total

  • 100 Historical Control Patients, knees - no FloSeal (retrospective)
  • 100 Patients, knees - 5mL FloSeal (retrospective)
  • 100 Patients, knees- 10mL FloSeal (prospective)
  • 100 Historical Control patients, hips—no FloSeal (retrospective)
  • 100 retrospective patients, hips—5mL of FloSeal (retrospective

Patients scheduled for Total Knee Arthroplasty will be asked if they wish to participate in the part of the study utilizing 10mL of FloSeal. These patient will be consented and the their data will be retrospectively gathered.

  Eligibility

Ages Eligible for Study:   18 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All Dr. Velyvis's patients that have had a Total Knee or Total Hip after January 1, 2007

Criteria

Inclusion Criteria:

  • Total Knee and Total Hip Patients
  • Surgical Time less than 2 hours

Exclusion Criteria:

  • Patients who require greater than 2 hour surgeries
  • Patients who are undergoing revision arthroplasty
  • Patients with known allergies to materials of bovine origin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00958945

Contacts
Contact: Charles Z Cyr, BA 760-766-1227 ccyr@desertortho.com

Locations
United States, California
Desert Orthopedic Center
Rancho Mirage, California, United States, 92211
Sponsors and Collaborators
Desert Orthopedic Center Medical Research Foundation
Baxter Healthcare Corporation
Investigators
Principal Investigator: John H. Velyvis,, MD Desert Orthopedic Center
  More Information

No publications provided

Responsible Party: John H. Velyvis, MD, Desert Orthopedic Center Medical Research Foundation
ClinicalTrials.gov Identifier: NCT00958945     History of Changes
Other Study ID Numbers: FloSeal
Study First Received: August 12, 2009
Last Updated: August 13, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Desert Orthopedic Center Medical Research Foundation:
Postoperative Hematocrit
Postoperative Hemoglobin

ClinicalTrials.gov processed this record on August 28, 2014